User login

You are here

Dr. Jerry Avorn

Dr. Jerry Avorn

Professor of Medicine, Harvard Medical School
Jerry Avorn, M.D., is a professor of Medicine at Harvard Medical School and chief of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital.  An internist, geriatrician, and drug epidemiologist, he studies the intended and adverse effects of  prescription drugs, physician prescribing practices, and medication policy. Dr. Avorn pioneered the “academic detailing” approach to continuing medical education, in which non-commercial, evidence-based information about drugs is provided to doctors through educational outreach programs run by public-sector sponsors. Such programs are now in use in the U.S., Canada, Australia, and Europe. He has served as a member of the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and is the author or co-author of over 400 papers in the medical literature on medication use and its outcomes, and of the book,  Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, now in its 11th printing.

More About Dr. Jerry Avorn

A critic of the pharmaceutical industry, Avorn believes companies are now somewhat more cautious, primarily because the FDA has become more vigilant.

Thursday, September 1, 2011

Innovation in the pharmaceutical industry is not coming from inside large companies, but from the purchase of biotech start-ups.

Monday, August 3, 2009

Even when good clinical trial data on a regimen or medicine exist, no coherent system ensures that the message gets out to doctors and patients. As a result, many treatment choices are driven by habit, old information or glitzy promotional campaigns.

Saturday, September 16, 2006

A letter to Congressman Henry Waxman expressing concerns regarding FDA enforcement.

Thursday, May 25, 2006

There is one area of biomedicine in which the government allows — even defends — a minimal standard that would be unacceptable anywhere else in research. It is the set of evidentiary requirements maintained by the FDA for the approval of new drugs.

Thursday, September 8, 2005

There are a few areas in which the government is indispensable. First is its public health role in making sure that all drugs on the market are safe and effective. The second crucial role for government is to make sure that every citizen has the capacity to pay for needed medical care, and that includes drugs.

Wednesday, December 1, 2004

Report on the state of the FDA's drug testing policies.

Tuesday, November 23, 2004

Vigilance disappears when it comes to requiring and analyzing the data that we need to be able to learn about the safety of the drugs once they're in widespread use.

Sunday, August 1, 2004
Thursday, September 8, 2005